Literature DB >> 12814263

Native disulfide bonds in plasma retinol-binding protein are not essential for all-trans-retinol-binding activity.

Gabriel O Reznik1, Yong Yu, George E Tarr, Charles R Cantor.   

Abstract

A human plasma retinol-binding protein (RBP) mutant, named RBP-S, has been designed and produced in which the six native cysteine residues, involved in the formation of three disulfide bonds, have been replaced with serine. A hexa-histidine tag was also added to the C-terminus of RBP for ease of purification. The removal of the disulfide bonds led to a decrease in the affinity of RBP for all trans-retinol. Data indicates all-trans-retinol binds RBP and RBP-S with Kd = 4 x 10(-8) M and 1 x 10(-7) M, respectively, at approximately 20 degrees C. RBP-S has reduced stability as compared to natural RBP below pH 8.0 and at room temperature. Circular dichroism in the far-UV shows that there is a relaxation of the RBP structure upon the removal of its disulfide bonds. Circular dichroism in the near-UV shows that in the absence of the disulfide bonds, the optical activity of RBP is higher in the 310-330 nm than in the 280-290 nm range. This work suggests that the three native disulfide bonds aid in the folding of RBP but are not essential to produce a soluble, active protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814263     DOI: 10.1021/pr0255809

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  2 in total

1.  Retinol binding protein IV purified from Escherichia coli using intein-mediated cleavage as a suitable replacement for serum sources.

Authors:  Chandler B Est; Regina M Murphy
Journal:  Protein Expr Purif       Date:  2019-11-19       Impact factor: 1.650

2.  Maternal Inheritance of a Recessive RBP4 Defect in Canine Congenital Eye Disease.

Authors:  Maria Kaukonen; Sean Woods; Saija Ahonen; Seppo Lemberg; Maarit Hellman; Marjo K Hytönen; Perttu Permi; Tom Glaser; Hannes Lohi
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.